As of 2024-12-11, the EV/EBITDA ratio of Newron Pharmaceuticals SpA (NWRN.SW) is -13.09. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NWRN.SW's latest enterprise value is 188.06 mil CHF. NWRN.SW's TTM EBITDA according to its financial statements is -14.36 mil CHF. Dividing these 2 quantities gives us the above NWRN.SW EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 2.9x - 7.9x | 4.1x |
| Forward P/E multiples | 5.3x - 7.7x | 5.5x |
| Fair Price | (5.59) - (7.20) | (5.24) |
| Upside | -172.5% - -193.4% | -168.0% |
| Date | EV/EBITDA |
| 2024-11-26 | -11.94 |
| 2024-11-25 | -12.13 |
| 2024-11-22 | -12.08 |
| 2024-11-21 | -12.19 |
| 2024-11-20 | -11.83 |
| 2024-11-19 | -11.83 |
| 2024-11-18 | -11.86 |
| 2024-11-15 | -12.21 |
| 2024-11-14 | -12.61 |
| 2024-11-13 | -12.40 |
| 2024-11-12 | -12.31 |
| 2024-11-11 | -12.84 |
| 2024-11-08 | -12.98 |
| 2024-11-07 | -12.83 |
| 2024-11-06 | -12.75 |
| 2024-11-05 | -13.04 |
| 2024-11-04 | -13.11 |
| 2024-11-01 | -13.37 |
| 2024-10-31 | -13.15 |
| 2024-10-30 | -13.42 |
| 2024-10-29 | -13.47 |
| 2024-10-28 | -13.84 |
| 2024-10-25 | -14.01 |
| 2024-10-24 | -13.83 |
| 2024-10-23 | -14.16 |
| 2024-10-22 | -14.39 |
| 2024-10-21 | -14.34 |
| 2024-10-18 | -14.37 |
| 2024-10-17 | -12.97 |
| 2024-10-16 | -12.97 |
| 2024-10-15 | -13.29 |
| 2024-10-14 | -12.69 |
| 2024-10-11 | -12.30 |
| 2024-10-10 | -12.19 |
| 2024-10-09 | -12.28 |
| 2024-10-08 | -12.53 |
| 2024-10-07 | -12.60 |
| 2024-10-04 | -12.67 |
| 2024-10-03 | -12.98 |
| 2024-10-02 | -12.94 |
| 2024-10-01 | -12.72 |
| 2024-09-30 | -12.60 |
| 2024-09-27 | -12.79 |
| 2024-09-26 | -12.49 |
| 2024-09-25 | -12.47 |
| 2024-09-24 | -12.60 |
| 2024-09-23 | -12.78 |
| 2024-09-20 | -13.62 |
| 2024-09-19 | -12.74 |
| 2024-09-18 | -13.54 |